Akero Therapeutics Inc. has announced the voluntary prepayment of its outstanding debt under a loan agreement with Hercules Capital, Inc. The company paid a total of $37.6 million, covering all principal, accrued interest, and associated fees. With this payment, Akero has fully satisfied and discharged its obligations under the agreement, effectively terminating the loan and related documents, except for certain warrants. The original loan, which allowed for borrowings up to $150 million, bore interest at a variable annual rate with a minimum of 7.65%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-223188), on September 29, 2025, and is solely responsible for the information contained therein.